Detalhe da pesquisa
1.
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Lancet
; 402(10405): 871-881, 2023 09 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37478883
2.
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Cancer
; 129(9): 1319-1350, 2023 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36848319
3.
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
Cancer
; 129(17): 2685-2693, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37129197
4.
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Oncologist
; 28(12): 1100-e1292, 2023 Dec 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37311055
5.
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial.
Lancet Oncol
; 23(10): 1321-1331, 2022 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36087590
6.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35358455
7.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35641218
8.
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer.
Future Oncol
; 18(16): 1963-1977, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-35354280
9.
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?
Biol Blood Marrow Transplant
; 26(10): 1759-1769, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32623078
10.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
N Engl J Med
; 376(25): 2415-2426, 2017 06 22.
Artigo
Inglês
| MEDLINE | ID: mdl-28636851
11.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31246283
12.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27718784
13.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29866947
14.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
Inglês
| MEDLINE | ID: mdl-26412456
15.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28651929
16.
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
BMC Cancer
; 17(1): 646, 2017 Sep 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28899363
17.
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Lancet Oncol
; 17(12): 1672-1682, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-27789196
18.
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Lancet Oncol
; 16(2): 187-99, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25601342
19.
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.
Oncologist
; 19(10): 1040-1, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25170013
20.
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets.
JTO Clin Res Rep
; 5(2): 100623, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38357092